Treatment of Akathisia with Lorazepam An Open Clinical Trial

Bartels, M.; Heide, K; Mann, Karl; Schied, H. W.

doi:10.1055/s-2007-1017074

Cited by 34 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, there was no change in the significance observed when drinking history markers were included. Other studies that have studied the efficacy of Propranolol [27] and Lorazepam [28] for treatment of akathisia have also reported time-course dependent alleviation of akathisia symptoms. There is substantial evidence that 5-HT2A antagonists are successful in treating akathisia symptoms, exclusively neuroleptic-induced akathisia [29].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Kurlawala

Vatsalya

2016

Journal of Addiction

View full text Add to dashboard Cite

Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia. Patients with clinically significant depression (high MADRS) reported a significant increase in akathisia measures at 6 W which eventually decreased at 12 W to below baseline levels. The increase in akathisia at 6 W corresponded with a significant increase in the patients' total drinks and heavy drinking pattern. Treatment with Quetiapine progressively lowered the occurrence of akathisia in alcohol dependent patients who do not show symptoms of depression. Quetiapine treatment lowered akathisia over time in heavy drinkers who had clinically significant symptoms of depression.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Akathisia has also been reported to be either primary or secondary to drug use [28, 29]. It is known that alterations in movement can be provoked by alcohol intake [32].…”

Section: Resultsmentioning

confidence: 99%

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Kurlawala

Vatsalya

2016

Journal of Addiction

View full text Add to dashboard Cite

show abstract

“…O estudo de Irwin et al, 15 25 os pacientes distribuídos para o grupo-placebo faziam uso concomitante de anticolinérgicos e benzodiazepínicos, o que pode ter influenciado para a alta resposta ao tratamento observada nesse grupo (60%), enquanto no estudo de Zubenko et al, 26 quatro entre cinco pacientes faziam uso concomitante de mesilato de benzotropina. Outro fator importante é o tempo de acompanhamento dos pacientes.…”

Section: Discussionunclassified

Tratamento farmacológico de acatisia induzida por antipsicóticos

Lima

Bacaltchuk

Ferraz

2001

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

INTRODUÇÃO: A acatisia induzida por antipsicóticos é um transtorno de movimento relacionado ao sistema motor e caracterizado por sensação subjetiva de inquietude interna, irritabilidade ou disforia que podem ser intensas. Associa-se à sensação física e objetiva de desassossego e a movimentos não discinéticos. Esse efeito adverso pode predispor à pobre adesão ao tratamento e, conseqüentemente, favorecer recaídas. Assim, a escolha do melhor tratamento contribui para o alívio do sofrimento dos pacientes e favorece o melhor prognóstico. OBJETIVOS: Avaliar a eficácia e a tolerabilidade dos betabloqueadores, benzodiazepínicos e anticolinérgicos, comparados ao placebo e entre si, no tratamento de acatisia induzida por antipsicóticos, independente de idade ou diagnóstico psiquiátrico. MÉTODOS: Todos os estudos controlados, obtidos a partir das estratégias de busca que compararam betabloqueadores de ação central, benzodiazepínicos ou anticolinérgicos ao placebo e entre si, independente de sexo, idade ou diagnóstico psiquiátrico, foram considerados para esta atualização. Até março de 1999, foram consultadas sete bases de dados eletrônicos, sendo também examinadas as referências bibliográficas dos artigos selecionados. RESULTADOS: São apresentados 22 estudos controlados, sendo 13 comparando betabloqueadores, benzodiazepínicos e anticolinérgicos ao placebo e nove comparando diretamente as intervenções entre si. CONCLUSÕES: As três intervenções farmacológicas demonstraram eficácia superior comparadas ao placebo. Betabloqueadores de ação central mostraram-se mais eficazes, quando comparados a betabloqueadores de ação periférica, benzodiazepínicos e anticolinérgicos.

show abstract

“…"Dosing frequencies for benzodiazepines are based on the minimal information available. [90][91][92][93][94][95] Adapted from references 46-59.…”

Section: P-blockers Akathisiamentioning

confidence: 99%

Treatment of Acute Neuroleptic‐Induced Movement Disorders

Tonda¹,

Guthrie²

1994

Pharmacotherapy

View full text Add to dashboard Cite

Acute extrapyramidal syndromes (EPS), including dystonia, parkinsonism, and akathisia, are associated with the use of virtually all neuroleptic agents. They may be alleviated by reducing the neuroleptic dosage, switching to a lower‐potency drug, or administering an adjunctive agent such as an anticholinergic, amantadine, benzodiazepine, or β‐blocker. Akathisia may be only partly dispelled by anticholinergics; alternatives are β‐blockers, benzodiazepines, and clonidine. In patients receiving long‐term neuroleptic therapy, both the prophylactic use and the duration of treatment with concomitant anti‐EPS drugs are controversial. Administration of prophylactic anti‐EPS drugs should be based on the likelihood that the patient will develop EPS, as well as the risk of adverse reactions resulting from extended use of the agents in a specific patient. The decision to continue anti‐EPS therapy should be reevaluated frequently, especially in elderly patients.

show abstract

Treatment of Akathisia with Lorazepam An Open Clinical Trial

Cited by 34 publications

References 4 publications

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Tratamento farmacológico de acatisia induzida por antipsicóticos

Treatment of Acute Neuroleptic‐Induced Movement Disorders

Contact Info

Product

Resources

About